Rheincell Therapeutics GmbH

RheinCell Therapeutics GmbH focuses on the GMP-compliant generation of human induced pluripotent stem cells (iPSC) from HLA-homozygous allogeneic umbilical cord blood (CB). The field of cell therapy is one of the most promising developments in modern medicine. But autologous approaches – based on cells made patient-by-patient – are extremely expensive and time consuming and thus, unsuited for routine applications. Instead, regenerative cell therapy requires allogenic off-the-shelf therapeutics. Our main focus is on setting up an iPS cell library consisting of various HLA-homozygous iPS master cell banks. The key idea behind is that only a limited number of iPSC lines are needed to set up an allogenic resource which prevents immune rejections in a large number of recipient patients. Thus, this master cell library serves as "off the shelf"- platform for various types of cell therapeutics and has the potential to become the starting material of any future iPSC-based cell therapy in the Western world – and beyond. Our expertise covers the entire spectrum of the medically oriented iPSC workflow and is based on our long-standing expertise in human iPSC technology. This includes cellular reprogramming under GMP conditions, GMP/ATMP-grade iPSC expansion and cryopreservation, targeted genetic manipulation (optional) and directed differentiation. Our interdisciplinary team of scientists and engineers is composed of experts in the areas of iPSC technology, stem cell differentiation, cell banking, medicine, GMP production and regulatory affairs. RheinCell scientists have outstanding expertise in cellular reprogramming and R&D of stem cells at an international level.